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Introduction
The identification, characterization, and clinical use of small-
molecule natural products revolutionized medicine in the 20th 
century. Nowhere is this fact more apparent than in the ability 
to treat bacterial infections with antibiotics. The morbidity and 
mortality associated with bacterial infections radically de-
creased with the discovery and application of antibiotics. The 
marvelous results observed with penicillin, evident in the semi-
nal work of Fleming, Corey, and Chain, led to a massive search 
for more antibiotics—a search that by the 1960s had yielded 
most of the structural classes of antibiotics currently in use. 
The effectiveness of the many antibiotics which thus became 
available contributed in large part to the declaration in 1967, by 
the United States Surgeon General, that “it was time to close 
the book on infectious diseases.” Unfortunately, by the 1970s 
this optimistic view had to be replaced by a much more cau-
tious perspective as the remarkable impact that antibiotics had 
had in modern medicine was being severely dampened by the 
widespread emergence of antibiotic resistance in pathogenic 
bacteria.
Today we recognize that antibiotic resistance is a critical 
problem in medicine. As early as 1945, when penicillin use was 
just beginning, Fleming expressed perceptive warnings that 
penicillin-resistant microbes would arise—a fact that was cor-
roborated in the hospital setting just a year later. Yet, it was not 
until the 1970s that antibiotic resistance was considered a real 
threat. By then, the fatalities caused by bacteria resistant to 
many antibiotics made it clear that the problem of resistance 
was serious and was not going to be easily controlled.
From an ecological perspective, the emergence of antibiotic 
resistance as a consequence of the widespread use of antibi-
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Resum. La incidència de la resistència als antibiòtics en bacte-
ris patògens està augmentant. Aquesta resistència es pot 
aconseguir mitjançant tres rutes clares: amb la inactivació del 
medicament, amb la modificació de la diana (target) i amb la 
disminució de la concentració del medicament que arriba a la 
diana. Des de fa temps se sap que els mecanismes de resis-
tència a antibiòtics específics es poden adquirir a través de mu-
tacions en el genoma bacterià o mitjançant l’addició de més 
gens durant el trasllat horitzontal de gens. Recentment, també 
s’ha descobert la importància dels diferents estats fisiològics 
per a la supervivència dels bacteris en presència d’antibiòtics. 
Ara és aparent que els bacteris tenen complexos mecanismes 
de resistència intrínsecs que sovint no es detecten en les pro-
ves estàndards de sensibilitat que es fan als antibiòtics en els 
laboratoris clínics. Entre aquests mecanismes intrínsecs, és de 
suma importància el desenvolupament de la resistència en 
bacteris que es troben en agregats associats a superfícies o 
biopel·lícules.
Paraules clau: resistència als antibiòtics · transferència 
gènica horitzontal · biopel·lícules
Abstract. The incidence of antibiotic resistance in pathogenic 
bacteria is rising. Antibiotic resistance can be achieved via 
three distinct routes: inactivation of the drug, modification of 
the target of action, and decreasing the concentration of drug 
that can reach the target. It has long been recognized that spe-
cific antibiotic resistance mechanisms can be acquired through 
mutation of the bacterial genome or by the addition of genes 
through horizontal gene transfer. Recent attention has also 
brought to light the importance of different physiological states 
for the survival of bacteria in the presence of antibiotics. It is 
now apparent that bacteria have complex, intrinsic resistance 
mechanisms that oftentimes are not detected in the standard 
antibiotic sensitivity tests performed in clinical laboratories. 
Paramount among these intrinsic mechanisms is the develop-
ment of resistance in bacteria found in surface-associated ag-
gregates or biofilms.
Keywords: antibiotic resistance · gene horizontal transfer · 
biofilms
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otics makes perfect sense. Antibiotic therapy, as wonderful as 
it is, amounts to a “scorched earth policy” to eradicate bacterial 
infections. The majority of antibiotics in clinical use today ex-
hibit a very broad spectrum of activity, affecting not only the 
target pathogen but nearly all of the bacteria present in the hu-
man body. In the presence of antibiotics, the rare resistant 
variants are at an enormous selective advantage—their growth 
is virtually unimpeded in the absence of competitors. In addi-
tion, it is now widely recognized that the antibiotic-sensitive 
non-pathogenic microbes that inhabit the human body are not 
merely commensal (present there simply to “have a meal” as 
that word implies) but rather play important beneficial symbiotic 
roles. By killing, or at least destabilizing, the communities of 
these beneficial symbionts, human health is compromised, fur-
ther complicating the effect of having an antibiotic-resistant 
pathogen present in the body.
Antibiotic-resistant bacterial infections are becoming in-
creasingly common in the clinical setting [1]. Given the de-
creasing numbers of novel antibiotics in the “drug development 
pipeline,” there is great concern among clinicians over the ap-
pearance of multiply-resistant bacterial strains of problematic 
pathogens such as Mycobacterium tuberculosis and Staphylo-
coccus aureus [2,3]. In this review, we discuss the recent ad-
vances in our understanding of the mechanisms that bacteria 
use to protect themselves from antibiotics and the means by 
which they acquire these defenses.
Mechanisms for bacterial resistance to antibiotics
All antibiotic resistance mechanisms fall into three broad cate-
gories: (1) direct inactivation of the active molecule; (2) altera-
tion of the organism’s sensitivity to the antibiotic by modifica-
tion of the target of action, and (3) reduction of the concentration 
of drug that reaches the target without modification of the 
compound itself (Fig. 1). The amazing diversity of antibiotic re-
sistance mechanisms is illustrated within each of these three 
categories.
The production of enzymes that degrade antibiotics falls into 
the first category of antibiotic resistance mechanisms. Since 
the discovery of b-lactamases, enzymes that degrade b-lactam 
antibiotics, many other antibiotic-modifying enzymes that con-
fer drug resistance have been found.
Decreased sensitivity to antibiotics due to target modifica-
tion, the second category defined above, encompasses many 
diverse microbial strategies. In entercocci, for example, chang-
es in the structure of the cell wall can render bacteria resistant 
to antibiotics such as vancomycin. Strains that have the vanA 
or vanB genes produce d-Ala- d-Lac peptidoglycan precursors 
that are 1000-fold less sensitive to vancomycin than the wild-
type d-Ala- d-Ala form. Also, a novel plasmid-encoded protein 
that confers resistance to quinolone antibiotics has been dis-
covered [4,5]. The protein protects DNA gyrase from quinolone 
inhibition without modifying the drug, but the protective mech-
anism is not known.
Most of the recent excitement in the field of antibiotic 
resistance has focused on the third category of drug resist-
ance mechanisms, reduction of the antibiotic concentra - 
tion. Because the efficacy of antibiotics depends on their 
ability to reach their target, factors that influence the accu-
mulation of drugs within the cell can be very effective in in-
creasing antibiotic resistance. This remainder of this article 
focuses on developments in this area of bacterial resistance 
to antibiotics.
Efflux pumps
Efflux pumps can affect both intrinsic and acquired resistance 
to many different antibiotics by using energy to reduce the cy-
toplasmic drug concentration to subtoxic levels. The analysis 
of genome sequences has shown that many bacteria appear 
to have multiple, putative efflux pumps [6,7,8]. The activity of 
these pumps contributes to the high levels of antibiotic resist-
ance exhibited by organisms such as Pseudomonas aerugi-
nosa [9].
Efflux pumps vary in both their specificity and mechanism. 
Single-drug transporters include ABC transporters and pumps 
driven by the proton-motive force. Many organisms also pos-
sess multidrug transporters that are capable of expelling a wide 
spectrum of structurally unrelated drugs from prokaryotic cells. 
Some multidrug resistance pumps, such as the Lmr ATP-de-
pendent ABC transporter from gram-positive bacteria, are ho-
mologous to efflux pumps that inhibit the action of chemothera-
peutic agents in eukaryotic cells [6]. It has been proposed that 
these efflux pumps act as “hydrophobic vacuum cleaners” by 
pumping non-polar compounds from the membrane to the ex-
terior of the cell [10]. Other multidrug exporters, such as QacA 
from S. aureus, use the proton-motive force to drive the removal 
of cationic and lipophilic antimicrobial compounds [11]. Until re-
cently, all of the known multidrug efflux pumps in gram-negative 












Fig. 1. Mechanisms of resistance to antibiotics (Ab).
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sion) transporter family or the SMR (small multidrug resistance) 
transporter family. However, a recently described macrolide-
specific efflux pump in Escherichia coli was found to be an ABC 
transporter [12]. Inducible multidrug efflux pumps are responsi-
ble for the intrinsic antibiotic resistance of many organisms and 
mutation of the regulatory elements that control the production 
of efflux pumps can lead to an increase in antibiotic resistance. 
For example, the MexAB-OprM in P. aeruginosa is normally 
positively regulated by the presence of antibiotics [13], yet mu-
tations in its regulator, mexR, lead to the overexpression of Mex-
AB-OprM, conferring increased resistance to b-lactam antibiot-
ics [14]. The broad-spectrum nature of efflux pumps and their 
ability to be transferred between microorganisms make them a 
serious threat to the efficacy of antibiotics in the clinical setting.
Cell permeability
The permeability of the bacterial cell envelope also greatly influ-
ences the ability of antibiotics to enter the cell. For example, the 
waxy, lipid-rich outer layers of mycobacteria render these or-
ganisms more resistant to killing by antimicrobial compounds. 
Gram-negative bacteria are protected from antibiotics by the 
negatively charged lipopolysaccharides in their outer mem-
brane, which limit the entry of hydrophobic antibiotics into the 
cell [15]. While small, hydrophilic molecules can cross the mem-
brane through non-specific porins, larger, more hydrophobic 
compounds, such as siderophores and vitamins, can only enter 
the cell through specialized porins. A recent report on a multid-
rug resistant strain of Enterobacter aerogenes showed that a 
single change in the sequence of an outer membrane porin can 
led to the decreased diffusion of b-lactam antibiotics into the 
cell, thus increasing resistance to these antibiotics [16].
In contrast to mycobacteria and gram-negative microorgan-
isms, most gram-positive organisms are not well-protected 
from penetration by antibiotics. The cell wall, a thick peptidog-
lycan layer, does not impede the movement of molecules less 
than 50 kDa. However, modifications of the cell wall’s structure 
can significantly decrease the permeability of the cell envelope 
to antibiotics. For instance, the intermediate vancomycin-re-
sistance phenotype in S. aureus is due to an increased amount 
of non-amidated glutamine residues in the peptidoglycan. It 
has been suggested that the increased resistance in these 
strains is due to the “affinity trapping” of vancomycin in the 
thickened cell wall [17,18].
Mechanisms for acquiring novel resistance
Bacteria acquire resistance through several different routes, in-
cluding mutation of the bacterial genome and acquisition of 
new genes through horizontal transfer of plasmids and trans-
posons. Researchers continue to identify new and exciting as-
pects of both of these acquisition mechanisms, as described 
below. Recently, researchers have also begun to address how 
different physiological states of bacteria specifically affect re-
sistance to antibiotics.
Mutation
Chromosomal mutations can lead to antibiotic resistance in a 
number of different ways. For example, a recently identified 
mutation in the 16S rRNA gene of a Helicobacter pylori isolate 
makes the cells resistant to tetracycline, presumably by altera-
tion of the antibiotic binding site [19]. Alternatively, as described 
above, mutations in regulators or regulatory regions can con-
tribute to antibiotic resistance by leading to the overproduction 
of either intrinsic resistance determinants, such as efflux 
pumps, or the target itself which may overcome total inhibition 
by the drug.
In recent years, much attention has been given to the idea 
that, within the host, mutations arise at a frequency that is high-
er than what is observed in vitro [20]. The presence of diverse 
variants within a single host was demonstrated in a recent 
study of E. coli strains taken from spatially separated cysts 
within a single patient receiving long-term antibiotic therapy. 
The E. coli isolates displayed many different phenotypic prop-
erties, including a range of antibiotic resistance levels, even 
though genetic analyses suggested that these strains were de-
rived from the same founder population [21]. A number of stud-
ies have suggested that a “mutator” phenotype is selected for 
within the host. Isolates of P. aeruginosa obtained from the 
sputum of cystic fibrosis (CF) patients with persistent infections 
had higher mutation rates than P. aeruginosa from non-CF pa-
tients [22]. Interestingly, the P. aeruginosa strains with higher 
rates of mutation showed significantly higher levels of resist-
ance to antibiotics. Genotype analysis of strains isolated from 
the same patient strongly suggests that the mutator pheno-
types actually evolve in the host over time. Mutator phenotypes 
have also been identified in other bacteria. A survey of over 600 
E. coli and Shigella isolates collected from different clinical 
samples found that strains associated with urinary tract infec-
tions had higher mutation frequencies than those implicated in 
septicemia [16]. Although the strains with higher mutation fre-
quencies were not more resistant to clinically relevant antibiot-
ics, the rate at which resistant colonies arose in the presence of 
high antibiotic concentrations was much higher in mutator 
strains than in the wild-type. A number of different factors could 
contribute to an increased mutation rate within the host, in-
cluding the presence of pockets within an infection that only 
receive low doses of antibiotics [22,23]. An understanding of 
the control of mutation rates in the host environment will con-
tribute to the design of antibiotic therapies that limit the selec-
tion for antibiotic-resistant bacteria.
Horizontal gene transfer
Since the discovery of the R factor, in the 1960s, it has been 
known that mobile genetic elements, such as plasmids and 
transposons, are important agents for the transfer of antibiotic 
resistance determinants between bacteria. These factors allow 
for the rapid, global dissemination of genes that confer antibi-
otic resistance, especially within hospital settings. Integrons, 
genetic elements that can encode several different antibiotic 
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resistance genes, have also contributed to the problem of anti-
biotic resistance in bacteria [24]. Indeed, integrons that contain 
up to eight different antibiotic resistance cassettes have been 
found in multidrug resistant clinical isolates [25]. Furthermore, 
superintegrons, which encode many different functions, have 
been found in Vibrio cholerae [26] and in non-pathogenic envi-
ronmental Pseudomonas strains [27], emphasizing the impor-
tance of integrons in the genetic exchange of elements, such 
as those that confer antibiotic resistance, among gram-nega-
tive bacteria.
Physiology-dependent resistance
Biofilm resistance to antibiotics. Bacterial biofilms that form 
on surfaces contain a high density of bacterial cells surrounded 
by an extracellular matrix. In general, bacteria within biofilms 
tolerate higher levels of antibiotics than comparable planktonic 
cells. The difficulties in treating biofilm-related infections on 
catheters and medical implants are thought to be due, at least 
in part, to the increased antibiotic resistance of biofilm bacteria. 
Although biofilms have some properties in common, their 
structure and composition depend on the component microor-
ganisms and environmental conditions. Thus, in different situa-
tions, the level of antibiotic resistance may vary and the factors 
that give rise to the increased resistance may differ.
Multiple factors likely to contribute to biofilm-associated an-
tibiotic resistance include slow growth rates, decreased diffu-
sion of antibiotics through the biofilm, the accumulation of en-
zymes that contribute to resistance, or the activation of stress 
responses in bacteria within the biofilm (reviewed recently in 
[28,29]). Several studies have examined the basis for biofilm 
antibiotic resistance in more detail. In Klebsiella pneumoniae 
biofilms, the diffusion of ampicillin and ciprofloxicin was not im-
peded by the biofilms themselves, but the levels of antibiotics 
within the biofilm were reduced due to the activity of b-lacta-
mases. Since b-lactamase production alone did not account 
for the resistance of biofilm bacteria to antibiotics, the authors 
suggested that other, uncharacterized elements are also im-
portant for resistance to antibiotics [30]. The factors that confer 
antibiotics resistance also depend on the drug itself. Multiple 
factors, including the presence of matrix, slow growth rates, 
and high cell densities, contribute to the increased resistance 
of Staphylococcus epidermidis biofilms to glycopeptides, but 
these factors do not explain the increased resistance of this 
bacterium to other classes of antibiotics [31].
The increased resistance of biofilm bacteria to antibiotics is 
due to several different mechanisms. Signals that control gene 
regulation, such as quorum-sensing compounds, are present 
in biofilms at levels that might regulate the expression of genes 
related to antibiotic resistance. Because the presence of efflux 
pumps is largely responsible for antibiotic resistance in many 
organisms, it was hypothesized that efflux pumps are more 
abundant in biofilm cells than in planktonic cells. However, mu-
tational analysis and gene expression studies of genes that en-
code known drug efflux pumps indicated that this is not neces-
sarily the case [30,32]. A comparison of the RNA expression 
profiles from P. aeruginosa planktonic cultures and biofilms 
identified several candidate genes that may contribute to the 
antibiotic resistance phenotype of biofilm cells [33]. For exam-
ple, increased expression of the tolA gene is hypothesized to 
alter the structure of lipopolysaccharides in the outer mem-
brane, making it more difficult for aminoglycoside antibiotics, 
such as tobramycin and gentamicin, to enter the cell. In addi-
tion, genes that encode porins or electron transport proteins 
are differentially expressed in biofilms and may also contribute 
to bacterial antibiotic resistance. When biofilms were chal-
lenged with high concentrations of tobramycin, two efflux sys-
tems as well as stress response proteins and several hypothet-
ical proteins were induced, but the role of these components in 
the antibiotic resistance of biofilm bacteria has not yet been 
tested directly.
Stationary-phase-induced resistance. It has been well-
documented that slow growth rates resulting from nutrient limi-
tation are accompanied by an increased resistance to multiple 
antibacterial compounds due to low metabolic activities and to 
decreased cell permeability [34]. Furthermore, slow growth is 
also correlated with the increased expression of multidrug ef-
flux genes, specifically, acrAB in E. coli, by an RpoS-independ-
ent mechanism [35]. A recent paper suggested that E. coli sta-
tionary-phase cultures produce a diffusible factor that is 
different from the known quorum-sensing systems that induc-
es resistance to antibiotics in growing E. coli cells. The nature 
of the signal or the response of cells to the signal is not yet 
known [36]. It has been proposed that in stationary-phase cul-
tures there are subpopulations of antibiotic-resistant “persister 
cells” that lead to the increased resistance to antibiotics [37]. 
Persister cells are not mutants and do not produce antibiotic-
resistant offspring in the absence of antibiotic. The mecha-
nisms by which persister cells are formed or the factors that 
contribute to their antibiotic resistance are not yet known.
Phenotypic variation within bacterial populations. Antibi-
otic resistance is often associated with decreased fitness in the 
absence of antibiotics [38]. Consequently, bacteria have devel-
oped mechanisms to mitigate the growth disadvantage con-
ferred by antibiotic resistance while ensuring their own survival 
in the presence of antibiotics. Small colony variants (SCV) of S. 
aureus appear in the presence of gentamicin both in vitro and 
in vivo [39]. Entry into the SCV form is reversible upon growth in 
antibiotic-free medium. Cycling between the resistant SCV and 
the antibiotic-sensitive larger colony form can occur multiple 
times, indicating that SCVs are not formed by mutation but 
rather through a regulatory mechanism or phase variation. 
Similarly, a recent paper by Drenkard and Ausubel [40] report-
ed that rough small colony variants (RSCV) frequently arise 
within P. aeruginosa populations at varying frequencies under 
different conditions. RSCVs have a number of phenotypic dif-
ferences from the “parental” form, including increased resist-
ance to multiple antibiotics. A gene that influences the frequen-
cy with which bacteria switch from the antibiotic-sensitive large 
colony variant to the resistant RSCV form has been identified, 
but the mechanism for switching between forms is not yet 
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known. Interestingly, RSCVs also have an increased rate of at-
tachment to plastic, perhaps due to a more hydrophobic cell 
surface, and form larger biofilms than wild-type bacteria. These 
findings suggest that there is a direct link between biofilm for-
mation and antibiotic resistance. Similarly, it will be interesting 
to explore the possible connection between the “persister 
cells” that form in stationary-phase cultures and the variants 
that arise in response to antibiotics, as both show increased 
antibiotic resistance. Even though the specific physiological 
basis for increased antibiotic resistance is not yet known, find-
ings such as these may contribute to the development of ther-
apies targeting pathogenic bacteria in the physiological states 
that predominate within the host.
Conclusions
In many cases, several different antibiotic resistance mecha-
nisms act in concert to protect a bacterium from the concen-
trations of antibiotics that are used in clinical settings [41,42]. 
Furthermore, some clinical isolates develop high levels of re-
sistance by combining different strategies for protection from 
exposure to antibiotics [43]. In our search for new antibiotics 
for therapeutic use, we must consider all of the intrinsic, muta-
tional, and physiological resistance mechanisms present in 
bacteria.
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